Abstract:ABSTRACT Botulinum neurotoxins (BoNTs) possess unique specificity for nerve terminals. They bind to the presynaptic membrane and then translocate intracellularly, where the light-chain endopeptidase cleaves the SNARE complex proteins, subverting the synaptic exocytosis responsible for acetylcholine release to the synaptic cleft. This inhibits acetylcholine binding to its receptor, causing paralysis. Binding, an obligate event for cell intoxication, is believed to occur through the heavy-chain C-terminal (HC) domain. It is followed by toxin translocation and entry into the cell cytoplasm, which is thought to be mediated by the heavy-chain N-terminal (HN) domain. Submolecular mapping analysis by using synthetic peptides spanning BoNT serotype A (BoNT/A) and mouse brain synaptosomes (SNPs) and protective antibodies against toxin from mice and cervical dystonia patients undergoing BoNT/A treatment revealed that not only regions of the HC domain but also regions of the HN domain are involved in the toxin binding process. Based on these findings, we expressed a peptide corresponding to the BoNT/A region comprising HN domain residues 729 to 845 (HN729–845). HN729–845 bound directly to mouse brain SNPs and substantially inhibited BoNT/A binding to SNPs. The binding involved gangliosides GT1b and GD1a and a few membrane lipids. The peptide bound to human or mouse neuroblastoma cells within 1 min. Peptide HN729–845 protected mice completely against a lethal BoNT/A dose (1.05 times the 100% lethal dose). This protective activity was obtained at a dose comparable to that of the peptide from positions 967 to 1296 in the HC domain. These findings strongly indicate that HN729–845 and, by extension, the HN domain are fully programmed and equipped to bind to neuronal cells and in the free state can even inhibit the binding of the toxin.

A Camelid Single-Domain Antibody Neutralizes Botulinum Neurotoxin A By Blocking Host Receptor Binding

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

A New Neutralizing Antibody Against Botulinum Neurotoxin B Recognizes the Protein Receptor Binding Sites for Synaptotagmins II.

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

Camelid Single Domain Antibodies (vhhs) As Neuronal Cell Intrabody Binding Agents and Inhibitors of Clostridium Botulinum Neurotoxin (bont) Proteases.

Neutralizing Antibodies Of Botulinum Neurotoxin Serotype A Screened From A Fully Synthetic Human Antibody Phage Display Library

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin

Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice

Binding Activity and Immunogenic Characterization of Recombinant C-terminal Quarter and Half of the Heavy Chain of Botulinum Neurotoxin Serotype A

Development and Preclinical Evaluation of a New F(ab')₂ Antitoxin Against Botulinum Neurotoxin Serotype A.

The C-Terminal Heavy-Chain Domain of Botulinum Neurotoxin A Is Not the Only Site That Binds Neurons, as the N-Terminal Heavy-Chain Domain Also Plays a Very Active Role in Toxin-Cell Binding and Interactions

A novel RRGW derived peptide is a promising inhibitor of BoNT/A

A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling

Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E

Characterization of Neutralizing Chimeric Heavy-Chain Antibodies Against Tetanus Toxin

Recombinant Anti-Botulinum Neurotoxin A Single-Chain Variable Fragment Antibody Generated Using a Phage Display System

Covalent modifiers of Botulinum neurotoxin counteract toxin persistence.

Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications